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a  b  s  t  r  a  c  t
Objective: The aim of this study was to analyze the correlation of vitamin D levels with clini-
cal parameters, bone mineral density (BMD), quality of life (QoL) and nailfold capillaroscopy
(NC) in patients with diffuse systemic sclerosis (SSc).
Methods: Thirty-eight female patients with diffuse SSc were analyzed regarding 25-
hydroxyvitamin D (25OHD) serum levels. At inclusion, organ involvement, autoantibodies,
modiﬁed Rodnan skin score (mRSS), Medsger Disease Severity Index (MDSI), body mass
index  (BMI), BMD, NC, Short-Form-36 Questionnaire (SF-36), and Health Assessment Ques-
tionnaire (HAQ), were performed through a standardized interview, physical examination
and  electronic chart review.
Results: Mean 25OHD serum level was 20.66 ± 8.20 ng/mL. Eleven percent of the patients
had 25OHD levels ≤10 ng/mL, 50% ≤20 ng/mL and 87% ≤30 ng/mL. Vitamin D serum levels
were positively correlated with BMI (r = 0.338, p = 0.038), BMD-total femur (r = 0.340, p = 0.037),
BMD-femoral neck (r = 0.384, p = 0.017), SF-36-Vitality (r = 0.385, p = 0.017), SF-36-Social Func-
tion  (r = 0.320, p = 0.050), SF-36-Emotional Role (r = 0.321, p = 0.049) and SF-36-Mental Health
(r  = 0.531, p = 0.0006) and were negatively correlated with HAQ-Reach (r = −0.328, p = 0.044)
and  HAQ-Grip Strength (r = −0.331, p = 0.042). A negative correlation with NC-diffuse devas-
cularization (p = 0.029) and NC-avascular area (p = 0.033) was also observed.
Conclusion: The present study provides novel evidence demonstrating that low levels of
25OHD have a negative impact in diffuse SSc QoL and further studies are needed to deﬁne
whether vitamin D supplementation can improve health related QoL in these patients. The
additional observation of a correlation with severe NC alterations suggests a possible roleof  25OHD in the underlying SSc vascular involvement.© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Baixos  níveis  séricos  de  vitamina  D  na  esclerose  sistêmica  difusa:







r  e  s  u  m  o
Objetivo: O objetivo deste estudo foi analisar a correlac¸ão entre os níveis de vitamina D
e  parâmetros clínicos, densidade mineral óssea (DMO), qualidade de vida (QV) e capilaro-
scopia periungueal (CPU) em pacientes com esclerose sistêmica difusa (ES).
Métodos: Mensuraram-se os níveis séricos de 25-hidroxivitamina D (25OHD) de 38 pacientes
do  sexo feminino com ES difusa. No momento da inclusão, analisaram-se o envolvimento
de  órgãos, autoanticorpos, escore cutâneo de Rodnan modiﬁcado (ERM), Medsger Disease
Severity Index (MDSI), índice de massa corporal (IMC), DMO, CPU, Short-Form-36 Ques-
tionnaire (SF-36) e Health Assessment Questionnaire (HAQ) por meio de uma entrevista
padronizada, exame físico e avaliac¸ão de prontuário eletrônico.
Resultados: A média do nível sérico de 25OHD foi de 20,66 ± 8,20 ng/mL. Dos pacientes, 11%
tinham níveis de 25OHD ≤ 10 ng/mL, 50% ≤ 20 ng/mL e 87% ≤ 30 ng/mL. Os níveis séricos de
vitamina D estiveram positivamente correlacionados com o IMC (r = 0,338, p = 0,038), DMO-
fêmur  total (r = 0,340, p = 0,037), DMO-colo femoral (r = 0,384, p = 0,017), SF-36-Vitalidade
(r  = 0,385, p = 0,017), SF-36-Aspecto social (r = 0,320, p = 0,050), SF-36-Aspecto emocional
(r  = 0,321, p = 0,049) e SF-36-Saúde mental (r = 0,531, p = 0,0006) e se correlacionaram neg-
ativamente com o HAQ-Alcance (r = −0,328, p = 0,044) e HAQ-forc¸a de preensão (r = −0,331,
p  = 0,042). Também foi observada uma correlac¸ão negativa com a CPU-desvascularizac¸ão
difusa (p = 0,029) e CPU-área avascular (p = 0,033).
Conclusão: O presente estudo fornece evidências novas de que níveis baixos de 25OHD
têm  um impacto negativo sobre a qualidade de vida de pacientes com ES difusa e que
são  necessários mais estudos para deﬁnir se a suplementac¸ão de vitamina D pode melho-
rar  a qualidade de vida relacionada com a saúde desses pacientes. A observac¸ão adicional
de  uma correlac¸ão com alterac¸ões graves na CPU sugere um possível papel da 25OHD no
envolvimento vascular subjacente da ES.
©  2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CCSigniﬁcance  &  innovations
1) Low vitamin D serum levels had a negative impact on phys-
ical and emotional domains of quality of life in diffuse SSc
patients.
2) Low vitamin D serum levels were correlated with severe
capillaroscopic ﬁndings.
3) Lower vitamin D levels were more  frequently observed in
patients with anti-Scl 70 positive.
Introduction
In the last two decades, the survival of patients with systemic
sclerosis (SSc) has signiﬁcantly improved.1,2 Nevertheless, SSc
can still cause increased disability and reduced quality of
life. Several factors can be involved with these conditions,
as disease subtype,3 gender,4 lung involvement,3 pruritus,5
fatigue,6 anxiety and depression.7,8 Hand, tendon and joint
involvement are other factors which can cause signiﬁcant
functional disability, leading to consequent disuse and wors-
ening of bone loss in patients with SSc,9,10 contributing to a
signiﬁcant impairment in the quality of life of these patients.10BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Low levels of 25-hydroxyvitamin D (25OHD) may also
contribute to the chronic inﬂammation, immunological
dysregulation and skeletal myopathy with a consequent
reduction in quality of life in autoimmune diseases.11,12 Stud-
ies evaluating vitamin D levels in SSc patients revealed a high
frequency of this condition and a possible association with
inﬂammation and pulmonary hypertension.13–18 There are,
however, no data regarding low vitamin D impact in quality
of life in these patients.
The aim of this study was therefore, to analyze the correla-
tion of vitamin D with quality of life, clinical parameters and
nailfold capillaroscopy (NC) in patients with diffuse SSc.
Methods
Patients
This is a cross-sectional study analyzing 38 diffuse SSc
patients who attended the Scleroderma Outpatient Clinic of
the University of São Paulo from May 2012 to May 2013.
All patients were classiﬁed as SSc according to the recent
EULAR/ACR criteria.19 Inclusion criteria were female gender;
age between 18 and 50 years; diffuse SSc according to LeRoy
et al. criteria20; capacity to understand the study and sign






















































wr e v b r a s r e u m a t o l
he informed consent. Exclusion criteria included: diagnosis of
nother connective tissue disease (CTD), organ failure (renal,
ulmonary or cardiac), gastric surgery, intestinal malabsorp-
ion, pregnancy, breast-feeding, severe infection and severe
hronic comorbidities.
linical  data
linical and demographic data were obtained through a
irect interview and a review of the electronic register
atabase. Esophageal involvement was considered when
atient referred clinical complaint of dysphagia and barium
sophagram revealed esophageal hypomotility. Interstitial
ung disease was considered when patient presented the
haracteristic “ground-glass” aspect at the chest high res-
lution computed tomography. Modiﬁed Rodnan skin score
mRSS) was used to determine the extension of the skin
nvolvement, classifying 17 anatomical sites from 0 (no skin
nvolvement) to 3 (severe skin involvement), with maximal
core of 51.21
Medsger Disease Severity Index (MDSI) was used to deter-
ine the SSc severity, deﬁning severity as the total effect of
isease on organ function. Scales were developed from 0 (no
ocumented involvement) to 4 (endstage disease) for each
rgan system: general (weight loss in kg), peripheral vascular
digital vascular ischemia), skin (mRSS), joint/tendon, muscle
weakness), gastrointestinal tract, lung, heart, and kidney.22
e  considered a severe disease when the MDSI was superior
o 3, according to previous studies.16
uality  of  life
ealth Assessment Questionnaire (HAQ) disability index (DI),
alidated to the Brazilian-Portuguese language23 was applied.
t contains 8 domains of activity (dressing, raising, eating,
alking, personal hygiene, reach, grip strength, and usual
aily activities) each of which has at least two questions, for a
otal of 20 items. For each item, patients report the amount of
ifﬁculty experienced performing the activity. A mean score
s calculated for each domain, ranging from 0 (without any
ifﬁculty) to 3 (unable to do). A composite HAQ score is calcu-
ated by dividing the summed domain scores by the number
f domains answered. The composite score is reported, falling
etween 0 (no impairment in function) and 3 (maximal impair-
ent of function) on an ordinal scale.24
The Short Form Questionnaire (SF-36), validated to the
razilian-Portuguese language,25 was also applied. The SF-36
onsists of 36 items organized into eight health domains
easuring physical functioning, role limitations due to
hysical problems, bodily pain, general health perceptions,
itality, social functioning, role limitations due to emotional
spects, and general mental health.26 Among these domains,
hysical functioning, physical role, and bodily pain evaluate
nly physical dimensions; social functioning, emotional role,
nd general mental health assess mental aspects; general
ealth perception and vitality evaluate both physical and
ental dimensions. In SF-36 domains, scores are rated so
hat higher values correspond to better conditions and lower
cores to worse conditions (range 0–100). The eight domains,
eighted according to normative data, are also combined into 6;5 6(4):337–344 339
a physical summary score (PSS) and a mental summary score
(MSS), which are scored from 0 to 100, with higher values
reﬂecting better health-related quality of life (HRQOL).27
Nailfold  capillaroscopy  (NC)
In vivo wide ﬁeld capillary microscopy (10 and 20 magniﬁca-
tions) was performed and graded by the same rheumatologist.
All ten digits were examined using a bifocal stereomicro-
scope (Zeiss, Germany) and lighting with a tungstenium lamp
shaded by a green lens in order to have a better visualiza-
tion. Immersion oil was applied for increasing transparency
of the skin and the whole nailfold region was examined,
including the edges. The normal ﬁndings for Brazilian pop-
ulation were deﬁned as previously described.28 Abnormal
ﬁndings were recorded on a standardized data sheet, as
follow: number of loops in a linear 1 mm wide, enlarge-
ment of capillary loops (absolute number, independently of
the size of the limbs), presence of bushy capillaries and the
avascular areas (loss of two consecutive loops of nail bed).
In this study, it was used the following scores: (1) Diffuse
devascularization (mean): 0 = normal (≥7 loops/mm); 1 = mild
(≥ 6 to <6.9 loops/mm); 2 = moderate (≥4 to <5.9 loops/mm);
3 = severe (<4 loops/mm); (2) Avascular areas: 0 = no avascu-
lar areas; 1 = 1 or 2 discontinuous avascular areas (>0.3 mm
and <0.5 mm);  2 = more  than two discontinuous avascular
areas (>0.3 mm and <0.5 mm);  3 = extense avascular areas
(>0.5 mm);  (3) Capillarectasia:  0 = rare (<8 capillaries); 1 = mild
(8–30 capillaries); 2 = moderate (31–40 capillaries); 3 = severe
(>40 capillaries); (4) Microhemorrhages:  0 = rare (<3/ﬁnger);
1 = mild (≥3 and <6/ﬁnger); 2 = moderate (≥6 and <8/ﬁnger);
3 = severe (≥8/ﬁnger).29 The SD pattern was deﬁned as the
presence of avascular areas or enlarged loops associated
with at least one additional SD-parameter (nailfold micro-
hemorrhages, reduced capillary density, enlarged loops and
avascular areas).30
NC was also classiﬁed in “early”, “active” and “late” pat-
terns, according to Cutolo et al.31 “Early pattern”: presence of
giant capillaries without loss of capillaries, “Active pattern”:
presence of combination of giant capillaries, loss of capillaries
and microhemorrhages. “Late pattern” presence of neoangio-
genesis and loss of capillaries.
Laboratory  data
Blood was collected in the morning, with a 12-h fasting.
Serum and plasma were aliquoted and kept at −80 ◦C on
Bone Metabolism Laboratory of Rheumatology Division, Fac-
ulty of Medicine. Laboratory parameters of bone metabolism
were measured in all patients: calcium, phosphate, alkaline
phosphate, parathormone, 25OHD serum levels and urinary
calcium. A radioimmunoassay technique (DiaSorin, Stillwa-
ter, MN, USA) with a lower detection limit of 5 ng/mL was
used to measure 25-hydroxyvitamin D (25OHD). The intra-
and inter-assay variation coefﬁcients in our laboratory were
10.5% and 17.8%, respectively. According to current recom-
mendations, 25OHD concentrations ≤30 ng/mL were deﬁned
as insufﬁciency,32,33 whereas values ≤10 ng/mL were classiﬁed
as deﬁciency.34
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Table 1 – Anthropometric, clinical, and laboratory
parameters in diffuse SSc patients.
Variables SSc
n = 38
Age, years (mean ± SD) 40.18 ± 7.27
Disease duration, years (mean ± SD) 8.25 ± 4.96
Modiﬁed Rodnan skin score (mean ± SD) 6.55 ± 4.67
Interstitial lungdisease (%) 79
Esophageal hypomotility (%) 63
Digital ulcers (%) 63
Acroosteolysis (%) 61
Joint involvement (%) 55
Calcinosis (%) 13






Medsger Disease Severity Index (mean ± SD) 6.40 ± 2.64
Osteoporosis (%) 37
25OH Vitamin D, ng/mL (mean ± SD) 20.66 ± 8.20
25OH Vitamin D ≤10 ng/mL (%) 11
25OH Vitamin D ≤20 ng/mL (%) 50
25OH Vitamin D ≤30 ng/mL (%) 87
PTH, pg/mL (mean ± SD) 49.87 ± 19.95
PTH ≥ 65 pg/mL (%) 21
Calcium, mg/dL (mean ± SD) 9.22 ± 0.61
24 h urinary calcium (mean ± SD) 107.85 ± 70.47340  r e v b r a s r e u m a t
The proﬁle of autoantibodies for each patient was also
obtained: antinuclear antibodies (ANA), anti-DNA topoiso-
merase I (anti-Scl 70).
Bone  mineral  density
BMD  was analyzed by dual-energy X-ray absorptiometry (DXA;
Hologic; QDR 4500, Bedford, MA,  USA) of the lumbar region
(L1-L4), total and femoral neck. Osteoporosis was deﬁned by
a T score ≤ −2.5 SD. Body mass index (BMI) was calculated
by measuring the weight and height of each patient during
interview.
Ethical  approval
All patients gave their written informed consent and the study
was approved by the Ethics Committee of the University of São
Paulo (Research protocol 0294/11).
Statistical  analysis
The results are reported as mean ± standard deviation
and percentage. The data were analyzed by t-test or
Mann–Whitney test to access the differences between the
groups. Prism program software was used to correlation of
Pearson; p values ≤0.05 were considered to be signiﬁcant.
Results
Thirty-eight female patients with diffuse SSc attending the
Scleroderma outpatient clinic of our institution were eligible
to participate in this study. The mean age was 40.18 ± 7.27
years, and the mean disease duration was 8.25 ± 4.96 years
(Table 1). Sixteen patients (42%) were currently using monthly
doses of intravenous cyclophosphamide, while 18 (47%)
patients referred previous use, and four (11%) had never used
it. Among the 18 patients who previously used cyclophos-
phamide, 15 (39%) were currently using azathioprine and three
(8%) were using mycophenolate mofetil. Sixteen patients (42%)
also referred previous use of methotrexate.
Among the clinical manifestations, interstitial lung dis-
ease (79%), esophageal hypomotility (63%), digital ulcers (63%)
and joint involvement (55%) were the most frequent ﬁnd-
ings. Hand deformities were observed in 21 patients (55%)
and subcutaneous calcinosis in 5 patients (13%). Other clin-
ical manifestations of SSc were present in <5% of the patients.
Mean mRSS was 6.55 ± 4.67, and mean MDSI was 6.40 ± 2.64
(Table 1).
Osteoporosis (total femur, femoral neck and/or lumbar
spine) was found in 37% of the diffuse SSc patients. Mean
25OHD serum levels were 20.66 ± 8.20 ng/mL. Four patients
(11%) had levels of 25OHD ≤ 10 ng/mL, 19 patients (50%) had
≤20 ng/mL and 33 patients (87%) had ≤30 ng/mL (Table 1).
Further analysis of vitamin D levels in patients with and
without esophageal involvement (20.40 ± 8.23 vs. 21.12 ± 8.43,
p = 0.80), interstitial lung disease (19.76 ± 7.90 vs. 24.05 ± 8.93,
p = 0.19), digital ulcers (20.63 ± 8.28 vs. 20.71 ± 8.36, p = 0.98),
hand deformities (18.70 ± 8.33 vs. 23.09 ± 7.57, p = 0.10),
joint involvement (19.40 ± 7.74 vs. 22.23 ± 8.71, p = 0.30), andANA, antinuclear antibody; SD, standard deviation.
calcinosis (17.40 ± 9.61 vs. 21.16 ± 8.02, p = 0.35) revealed no
association of lower serum levels of this hormone and the dif-
ferent clinical manifestations. Nevertheless, anti-Scl 70 posi-
tive patients presented lower levels of vitamin D compared to
anti-Scl 70 negative (17.94 ± 7.10 vs. 23.40 ± 8.49, p = 0.039).
The possible correlations of vitamin D with demographic,
bone mineral density and nailfold capillaroscopy data was
performed and revealed a positive correlation with weight
(r = 0.333; p = 0.041), BMI (r = 0.338; p = 0.038), total femur BMD
(r = 0.340; p = 0.037), femoral neck BMD (r = 0.384; p = 0.017) and
fat mass (r = 0.323; p = 0.048). No correlation was observed
between 25OHD with age, disease duration, mRSS and MDSI
(Table 2).
All the patients presented the characteristic “SD pat-
tern” and the mean NC score was 5.50 ± 2.29. The mean
scores for capillaroscopic characteristics were: diffuse devas-
cularization = 1.71 ± 0.73; avascular areas = 1.92 ± 0.88; capil-
lary ectasia = 0.42 ± 0.76; and microhemorrhages = 0.45 ± 0.92.
Eighteen (47%) patients presented “active pattern” and 20
(53%) “late pattern” in NC. There was negative correlation
among 25OHD serum levels and diffuse devascularization
(r = −0.355; p = 0.029) and avascular areas (r = −0.347; p = 0.033)
(Table 2).
Mean SF-36 was 53.05 ± 8.71. The analysis of the 8 domains
of SF-36 showed a positive correlation among 25OHD serum
levels and SF-36-Vitality (r = 0.385; p = 0.017); SF-36-Social
Function (r = 0.320; p = 0.050); SF-36-Mental Health (r = 0.531;
p = 0.0006); and SF-Emotional Role (r = 0.321; p = 0.049) (Table 3).
Mean total HAQ was 0.68 ± 0.25. Analysis of the 8 domains
revealed a negative correlation of 25OHD serum levels
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Table 2 – Correlation of 25OHD with age, weight, height, body mass index (BMI), disease duration, bone mineral density
(BMD), nailfold capillaroscopy (NC), Medsger Disease Severity Index (MDSI) and Modiﬁed Rodnan Skin Score (mRSS) in 38
diffuse SSc patients.
25OHD Mean ± SD Pearson r p-Value
Age, years 40.18 ± 7.27 0.289 0.079
Weight, kg 63.78 ± 14.20 0.333 0.041
Height, m 1.58 ± 0.06 0.149 0.373
BMI, kg/m2 25.49 ± 4.96 0.338 0.038
Disease duration, years 8.25  ± 4.96 −0.280 0.088
L1–L4 BMD, g/cm2 0.917 ± 0.163 0.239 0.149
Total femur BMD, g/cm2 0.795 ± 0.167 0.340 0.037
Femoral neck BMD, g/cm2 0.710 ± 0.130 0.384 0.017
Distal radius BMD, g/cm2 0.516 ± 0.071 0.272 0.099
Fat mass, g 23.05 ± 8.17 0.323 0.048
Lean mass, g 38.38 ± 7.11 0.264 0.109
NC
Diffuse devascularization 1.71 ± 0.73 −0.355 0.029
Avascular area 1.92 ± 0.88 −0.347 0.033
Capillar ectasia 0.42 ± 0.76 0.114 0.498
Microhemorrhages 0.45 ± 0.92 0.164 0.325
MDSI 6.40 ± 2.64 −0.277 0.092
mRSS 6.55 ± 4.67 0.028 0.866
Table 3 – Correlation of 25OHD with Short Form Questionnaire (SF-36) and Health Assessment Questionnaire (HAQ) in 38
diffuse SSc patients.
25OHD Mean ± SD Pearson r p-Value
SF-36
Physical functioning 51.58 ± 27.46 0.270 0.101
Physical role 42.76 ± 42.28 0.074 0.659
Bodily pain 51.80 ± 27.30 0.245 0.139
General health 49.40 ± 25.30 0.309 0.059
Vitality 48.95 ± 22.73 0.385 0.017
Social function 70.39 ± 26.22 0.320 0.050
Emotional role 48.24 ± 45.65 0.321 0.049
Mental health 61.26 ± 16.35 0.531 0.0006
HAQ
Dressing 0.82 ± 0.77 −0.231 0.164
Raising 0.54 ± 0.61 −0.293 0.075
Eating 0.58 ± 0.67 −0.042 0.803
Walking 0.32 ± 0.47 −0.154 0.356
Hygiene 0.43 ± 0.53 −0.206 0.214
Reach 1.01 ± 0.80 −0.328 0.044











cActivities 0.87 ± 0.73 
ith HAQ-Reach (r = −0.328; p = 0.044) and HAQ-Grip Strength
r = −0.331; p = 0.042) (Table 3).
iscussion
his is the ﬁrst study identifying that vitamin D is signiﬁ-
antly correlated with QoL and severe capillaroscopic ﬁndings
n diffuse SSc. The decision to focus the analysis on dif-
use SSc and female gender was important to select a more
omogeneous group of patients in a heterogeneous disease
s SSc. Considering that limited and diffuse SSc subtypes
an present distinct proﬁles of organ involvement,20,35 they
ould affect QoL in a distinct way; in fact, diffuse SSc patients−0.197 0.235
present higher global and local disability, and lower QoL  than
limited SSc patients.36 The inclusion of only female gender
may be relevant since a possible association of gender with
disease clinical expression and anxiety in patients with SSc
was reported.4 In fact, a recent cross-sectional study observed
that psychiatric symptoms, particularly anxiety and depres-
sion, are more  associated with increased disability and altered
health-related QoL in SSc patients, than with disease-speciﬁc
organ manifestations.8 Moreover, hand deformity, a complica-
tion which is known to have a deleterious effect in disability
36and reduced health-related QoL in SSc, is reported to have a
positive association with anti-Scl70 antibody.37
We  conﬁrmed previous studies showing a high frequency
of low levels of 25OHD and higher risk for autoimmune
 o l . 2
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diseases,11,12 including diffuse SSc.13–18 Although there was
no association with SSc- speciﬁc organ manifestations, there
was a statistical association with SSc-speciﬁc autoantibody,
the anti-Scl70 (a known biomarker of diffuse SSc), which pre-
sented lower levels of 25OHD.
Despite recent studies have clearly evidenced a high preva-
lence of 25OHD deﬁciency in SSc, its role has not been
completely understood in SSc disease pathogenesis. Although
it could be advisable to regularly check 25OHD status in
these patients, there is no consensus that 25OHD supple-
mentation might be sufﬁcient to modulate immunological
homeostasis, and reduce disease activity or severity.13,14 Sev-
eral studies about lower serum 25OHD concentrations are
linked with various clinical aspects in SSc patients. In our
study, the presence of osteoporosis/osteopenia was frequent
in our patients and the positive correlation between 25OHD
and total femur and femoral neck BMD  was also found in
the literature, but there is no clear demonstration about
the relationship of 25OHD deﬁciency with low bone mineral
density.15,17,38
As vitamin D supplementation was not a routine practice
for the Outpatient Scleroderma Clinic before this study, no
scleroderma patient was previously supplemented with vita-
min  D.
Importantly, the main causes of vitamin D deﬁciency, such
as intestinal malabsorption, gastrectomy, kidney and liver fail-
ure, were exclusion criteria for this study. As in Brazil the
seasons are not clearly demonstrated as they are in European
and North American countries, the patients participating in
this study had their clinical and laboratory evaluation con-
secutively, from May 2012 to May 2013, regardless of the
season. Reduced sun exposure for psychological and social
reasons was not evaluated in our study and may contribute
to this deﬁciency in scleroderma patients.14 Of note, one
fourth of patients had high PTH levels, which may reﬂect
secondary hyperparathyroidism associated with a silent mal-
absorption. In limited SSc, vitamin D deﬁciency was correlated
with hyperparathyroidism and the latter was associated with
acroosteolysis.39
Another important concern is the interaction among vita-
min  D and the drugs used in the long term treatment of SSc.
Some of these drugs, like cyclophosphamide, calcium chan-
nel blockers (ex. nifedipine) and proton-pump inhibitors (ex.
omeprazol), which are metabolized through cytochrome P450
3A4 (CYP3A4), could theoretically interfere with vitamin D
metabolism.40 However, there are no speciﬁc studies analyz-
ing its effects on bone metabolism in SSc.
Interestingly, this is the ﬁrst study to reveal the importance
of vitamin D for several physical and emotional domains of
quality of life in diffuse SSc. Vitamin D was correlated with
vitality, social function, mental health and emotional role in
SF-36. This ﬁnding is further supported by the recent obser-
vation in community-based elderly Canadians demonstrating
the importance of this hormone in health quality of life.41
The signiﬁcant correlation of vitamin D in SSc patients with
mental health observed here in is consistent with the hypoth-
esis of a recent systematic review in more  than 30,000 adults
demonstrating that low vitamin D concentration is associated
with depression42 and also with anxiety in a large community
sample.41 0 1 6;5 6(4):337–344
The novel correlation of low vitamin D with HAQ reach and
grip strength domains may be related to the fact that vitamin D
improves muscle strength, and its supplementation has a pos-
itive effect in mobility and physical function.43 In fact, higher
levels are associated with a better mobility and usual activ-
ities performance.43 In this regard, future studies analyzing
hand grip in diffuse SSc will be interesting, since vitamin D
status was reported to predict hand-grip strength in young
adult women.44
The well-established role of capillaroscopy for the early
diagnosis of SSc, and its inclusion in the recent ACR/EULAR
classiﬁcation criteria, combined with its potential for moni-
toring disease progression and treatment response, makes NC
an important assessment in clinical practice and research.31,45
In the present study, as most patients presented late diffuse
SSc, the “active” and the “late” capillaroscopic patterns were
predominant. We conﬁrmed the negative correlation of 25OHD
serum levels and NC – diffuse devascularization and avascular
areas,14 although not associated with lung involvement. This
ﬁnding raises the hypothesis that low levels of this hormone
may contribute to endothelial dysfunction in SSc. In fact, low
vitamin D status was associated with arterial dysfunction
and vitamin D supplementation was reported to counteract
this endothelial alteration in asymptomatic subjects and dia-
betes patients.46,47 Current evidence indicates that vitamin
D supplementation may have a small to moderate effect on
quality of life when used on a short-term basis in diseased
populations. However, the evidence for a beneﬁcial effect of
long-term vitamin D supplementation on health-related qual-
ity of life is lacking.48–50
The present study provides novel evidence demonstrating
that low levels of 25OHD can contribute to a decreased QoL
in patients with diffuse SSc through its association with the
underlying vascular involvement (worst capillaroscopic ﬁnd-
ings) and the autoantibody production (anti-Scl70).
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